5 TRT Myths That Refuse to Die (And What the Data Actually Says)

If you spend any time in online communities discussing testosterone replacement therapy (TRT), you will hear the same warnings repeated ad nauseam. TRT will give you a heart attack. It causes cancer. You will be on it forever. Your testicles will shrivel. Your liver will fail. Your blood will become thick as motor oil.

These warnings are so pervasive that they have calcified into cultural lore. Men repeat them to each other with absolute certainty despite the fact that most of them are either completely fabricated or represent a profound misunderstanding of the clinical evidence. This article examines the five most persistent TRT myths and holds each one up against what the peer-reviewed research actually says. Spoiler alert: most of what circulates online is wrong.

Myth 1: TRT Causes Heart Attacks and Sudden Cardiac Death

This is perhaps the most pervasive myth about testosterone therapy. The narrative is simple: higher testosterone = thicker blood = heart attack. For decades, this belief dominated medical discourse. But the clinical evidence paints a very different picture.

A landmark 2010 meta-analysis in the Journal of Sexual Medicine reviewed 19 randomized controlled trials spanning over 6,000 men and found no increased risk of major adverse cardiac events in men receiving testosterone therapy. The TTrials study (2016), which followed over 790 men across 12 clinical sites, found that testosterone therapy did not increase the risk of cardiovascular events over 3 years of treatment, even in older men.

What about hematocrit (red blood cell count)? Yes, testosterone increases hematocrit, sometimes significantly. But the link between moderate hematocrit elevation and cardiac events is far weaker than the myth suggests. The Androgel study (2012) showed that even men with elevated hematocrit from TRT had no increased cardiovascular outcomes.

The truth is more nuanced: men on TRT need regular bloodwork to monitor hematocrit, lipids, and other markers. But monitored TRT does not significantly increase cardiac risk for most men. Unmonitored TRT, or doses that push testosterone to supraphysiological levels, is a different story entirely.

Myth 2: TRT Causes Prostate Cancer

If there is one claim that causes men the most anxiety about TRT, it is this one: testosterone causes prostate cancer. The fear is so ingrained that many urologists still decline to offer TRT to men with a family history of prostate cancer, despite mounting evidence that this fear is unfounded.

The Endocrine Society reviewed all available evidence in their 2018 clinical practice guidelines and concluded that testosterone therapy does not increase prostate cancer risk in men with no prior history of cancer. Multiple long-term studies, including the Boston Area Community Health (BACH) study, found no relationship between testosterone levels and incident prostate cancer.

One critical point: testosterone does not cause prostate cancer. But if a man has subclinical prostate cancer, testosterone might accelerate its growth. This is why baseline PSA and DRE screening are essential before starting TRT, and why ongoing monitoring is mandatory.

Myth 3: You Will Be on TRT Forever

The claim: once you start TRT, your testicles stop producing testosterone and you can never come off. This is presented as an irrevocable life sentence. The reality is far different.

TRT does suppress natural testosterone production—this is called secondary hypogonadism. But suppression is not the same as permanent damage. Most men who discontinue TRT will experience recovery of testicular function within 6–12 months. Studies show that testicles can retain the ability to produce testosterone even after years of exogenous therapy.

Some men will experience permanent suppression—perhaps 5–10% of long-term users. But the majority recover. The narrative of TRT as a permanent one-way door is simply not supported by the data. Men come off TRT successfully all the time.

Myth 4: TRT Will Make You Aggressive or "Roid Rage"

This myth is particularly pernicious because it plays on ancient ideas about testosterone as a "rage hormone." The claim goes: higher testosterone = more aggressive = dangerous behavior.

The evidence shows the opposite. In clinical trials, men on TRT do not show increased aggression or mood disturbance. If anything, most men report *improved* mood and reduced depression when testosterone levels are normalized. A 2019 meta-analysis found no association between testosterone therapy and aggressive behavior in randomized controlled trials.

The "roid rage" phenomenon appears to be associated with supraphysiological doses (doses far higher than what is used in clinical TRT) combined with other psychological and social factors. Men receiving medically supervised TRT at replacement doses do not become aggressive.

Myth 5: TRT Will Destroy Your Liver and Kidneys

Anecdotal horror stories circulate about men on TRT developing kidney disease or liver failure. The mechanism is rarely explained—just vague warnings about "liver toxicity."

Testosterone therapy does not significantly impact liver or kidney function in men with normal baseline function. Liver enzyme elevation from testosterone is rare and typically mild. Kidney disease from TRT is exceptionally uncommon.

The confusion likely stems from the fact that *oral* anabolic steroids (17-alpha alkylated compounds) can cause hepatic stress due to first-pass metabolism. But injectable testosterone therapy—the form used in clinical TRT—does not have this risk profile.

The Real Risks of TRT (What You Should Actually Worry About)

If these five myths are overblown, what are the actual risks of TRT that deserve attention?

• Polycythemia: Elevated hematocrit is common and requires monitoring. Severe cases need therapeutic phlebotomy.
• Lipid changes: TRT can lower HDL and increase triglycerides. Regular lipid panels are essential.
• Injection site reactions: Pain, infection, or sterile abscess at injection sites.
• Dose-dependent side effects: Acne, hair loss, and gynecomastia become more likely at supraphysiological doses.
• Sleep apnea: TRT can worsen pre-existing sleep apnea or unmask subclinical disease.

These are real. These warrant monitoring. But they are not the existential threats that mythology suggests. With proper baseline screening, dose optimization, and ongoing bloodwork, the risk-benefit profile of TRT is favorable for men with genuine hypogonadism.

Conclusion: Evidence Over Mythology

The five myths examined here persist because they are emotionally compelling and because misinformation spreads faster than correction. But when you hold them up against actual clinical data, they collapse.

TRT is not a magic cure. It is not risk-free. But it is also not the physiological disaster that online mythology suggests. For men with confirmed hypogonadism who want to restore testosterone to normal levels, the evidence supports a trial of therapy under proper medical supervision.

The key is informed decision-making based on evidence, not mythology. Get baseline testing. Find a knowledgeable provider. Monitor regularly. Adjust based on response. That is the science-based approach to TRT.